RKDA Relative Valuation
RKDA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RKDA is overvalued; if below, it's undervalued.
Historical Valuation
Arcadia Biosciences Inc (RKDA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.40 is considered Undervalued compared with the five-year average of -1.68. The fair price of Arcadia Biosciences Inc (RKDA) is between 4.07 to 5.55 according to relative valuation methord. Compared to the current price of 2.41 USD , Arcadia Biosciences Inc is Undervalued By 40.76%.
Relative Value
Fair Zone
4.07-5.55
Current Price：2.41
40.76%
Undervalued
-0.87
PE
1Y
3Y
5Y
0.89
EV/EBITDA
Arcadia Biosciences Inc. (RKDA) has a current EV/EBITDA of 0.89. The 5-year average EV/EBITDA is 0.20. The thresholds are as follows: Strongly Undervalued below -1.82, Undervalued between -1.82 and -0.81, Fairly Valued between 1.21 and -0.81, Overvalued between 1.21 and 2.22, and Strongly Overvalued above 2.22. The current Forward EV/EBITDA of 0.89 falls within the Historic Trend Line -Fairly Valued range.
0.89
EV/EBIT
Arcadia Biosciences Inc. (RKDA) has a current EV/EBIT of 0.89. The 5-year average EV/EBIT is 0.35. The thresholds are as follows: Strongly Undervalued below -2.12, Undervalued between -2.12 and -0.88, Fairly Valued between 1.59 and -0.88, Overvalued between 1.59 and 2.83, and Strongly Overvalued above 2.83. The current Forward EV/EBIT of 0.89 falls within the Historic Trend Line -Fairly Valued range.
0.40
PS
Arcadia Biosciences Inc. (RKDA) has a current PS of 0.40. The 5-year average PS is 1.62. The thresholds are as follows: Strongly Undervalued below -1.92, Undervalued between -1.92 and -0.15, Fairly Valued between 3.38 and -0.15, Overvalued between 3.38 and 5.15, and Strongly Overvalued above 5.15. The current Forward PS of 0.40 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Arcadia Biosciences Inc. (RKDA) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Arcadia Biosciences Inc. (RKDA) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.83. The thresholds are as follows: Strongly Undervalued below -3.61, Undervalued between -3.61 and -2.22, Fairly Valued between 0.56 and -2.22, Overvalued between 0.56 and 1.94, and Strongly Overvalued above 1.94. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Arcadia Biosciences Inc (RKDA) has a current Price-to-Book (P/B) ratio of 0.54. Compared to its 3-year average P/B ratio of 0.49 , the current P/B ratio is approximately 9.83% higher. Relative to its 5-year average P/B ratio of 0.68, the current P/B ratio is about -20.46% higher. Arcadia Biosciences Inc (RKDA) has a Forward Free Cash Flow (FCF) yield of approximately -206.18%. Compared to its 3-year average FCF yield of -283.97%, the current FCF yield is approximately -27.39% lower. Relative to its 5-year average FCF yield of -209.57% , the current FCF yield is about -1.62% lower.
0.54
P/B
Median3y
0.49
Median5y
0.68
-206.18
FCF Yield
Median3y
-283.97
Median5y
-209.57
Competitors Valuation Multiple
The average P/S ratio for RKDA's competitors is 0.74, providing a benchmark for relative valuation. Arcadia Biosciences Inc Corp (RKDA) exhibits a P/S ratio of 0.40, which is -45.26% above the industry average. Given its robust revenue growth of -15.29%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RKDA decreased by 50.21% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.23 to -0.58.
The secondary factor is the Revenue Growth, contributed -15.29%to the performance.
Overall, the performance of RKDA in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
Frequently Asked Questions
Is Arcadia Biosciences Inc (RKDA) currently overvalued or undervalued?
Arcadia Biosciences Inc (RKDA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.40 is considered Undervalued compared with the five-year average of -1.68. The fair price of Arcadia Biosciences Inc (RKDA) is between 4.07 to 5.55 according to relative valuation methord. Compared to the current price of 2.41 USD , Arcadia Biosciences Inc is Undervalued By 40.76% .
What is Arcadia Biosciences Inc (RKDA) fair value?
RKDA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Arcadia Biosciences Inc (RKDA) is between 4.07 to 5.55 according to relative valuation methord.
How does RKDA's valuation metrics compare to the industry average?
The average P/S ratio for RKDA's competitors is 0.74, providing a benchmark for relative valuation. Arcadia Biosciences Inc Corp (RKDA) exhibits a P/S ratio of 0.40, which is -45.26% above the industry average. Given its robust revenue growth of -15.29%, this premium appears unsustainable.
What is the current P/B ratio for Arcadia Biosciences Inc (RKDA) as of Jan 08 2026?
As of Jan 08 2026, Arcadia Biosciences Inc (RKDA) has a P/B ratio of 0.54. This indicates that the market values RKDA at 0.54 times its book value.
What is the current FCF Yield for Arcadia Biosciences Inc (RKDA) as of Jan 08 2026?
As of Jan 08 2026, Arcadia Biosciences Inc (RKDA) has a FCF Yield of -206.18%. This means that for every dollar of Arcadia Biosciences Inc’s market capitalization, the company generates -206.18 cents in free cash flow.
What is the current Forward P/E ratio for Arcadia Biosciences Inc (RKDA) as of Jan 08 2026?
As of Jan 08 2026, Arcadia Biosciences Inc (RKDA) has a Forward P/E ratio of -0.87. This means the market is willing to pay $-0.87 for every dollar of Arcadia Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Arcadia Biosciences Inc (RKDA) as of Jan 08 2026?
As of Jan 08 2026, Arcadia Biosciences Inc (RKDA) has a Forward P/S ratio of 0.40. This means the market is valuing RKDA at $0.40 for every dollar of expected revenue over the next 12 months.